Compare Elastic NV (ESTC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Recursion Pharmaceuticals Inc — how do they compare? Elastic NV trades at $61.99 (market cap $6.47B), while Recursion Pharmaceuticals Inc trades at $3.15 (market cap $1.75B). The key difference: Elastic NV is far larger — about 3.7× Recursion Pharmaceuticals Inc's market cap, and Elastic NV is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ESTC | RXRX | |
|---|---|---|
Market Cap | $6.47B | $1.75B |
Sector | Technology | Health |
52-Week High | $94.47 | $6.79 |
52-Week Low | $43.30 | $2.84 |
Enterprise Value | $5.69B | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic N.V. (ESTC) trades at $61.75, down 0.91% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust revenue growth, reaching $1.48B in 2025 with expectations of $1.7B in 2026, and has consistently beaten EPS estimates in recent quarters. Recent positive news includes Elastic Security achieving a 100% malware protection score and being named a Leader in IDC MarketScape's SIEM 2026 assessment.
Wall Street maintains a bullish outlook with 23 buy ratings and a $73 consensus price target, representing 18% upside. However, investors should note the high EV/EBITDA ratio of 164.13 and ongoing legal investigations highlighted in recent news. The stock's current RSI levels suggest potential overbought conditions, while strong profitability metrics and institutional support provide fundamental backing.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
